PRE
Title: Coronavirus disease 2019
ID: 984215692
FULLTEXT: <td class="diff-addedline"><div>&lt;!-- DO NOT INTERFERE WITH THE SECTION BEGIN/END TAGS, AS IT WILL BREAK THE PANDEMIC ARTICLE --&gt;&lt;section begin="Spread" /&gt;[[Transmission of COVID-19|COVID-19 spreads]] most often when people are physically close.{{efn|Known as "close contact" which is variously defined, including within ~1.8 metres (six feet) by the US [[Centers for Disease Control and Prevention]] (CDC), and being face to face for at least 15 minutes, or sharing an enclosed space for a prolonged period such as 2 hours, by the Australian Health Department.&lt;ref&gt;{{cite web |title=Quarantine for coronavirus (COVID-19) |url=https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/how-to-protect-yourself-and-others-from-coronavirus-covid-19/quarantine-for-coronavirus-covid-19#what-is-a-close-contact |website=Australian Government Department of Health |accessdate=25 September 2020}}&lt;/ref&gt;&lt;ref name="CDCTrans"&gt;{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html |title=How COVID-19 Spreads |date=18 September 2020 |website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |url-status=live |archive-url=https://web.archive.org/web/20200919224920/https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Ftransmission.html |archive-date=19 September 2020 |access-date=20 September 2020}}&lt;/ref&gt;|name=|group=}} It spreads very easily and sustainably through the air, primarily via [[Respiratory droplet|small droplets]] <ins class="diffchange diffchange-inline">or</ins> [[Airborne transmission|aerosols]], as an infected person breathes, coughs, sneezes, talks, or sings.&lt;ref name="CDCTrans" /&gt;&lt;ref name="ECDCTRANSMIT"&gt;{{Cite web|title=Transmission of COVID-19|url=https://www.ecdc.europa.eu/en/covid-19/latest-evidence/transmission|access-date=12 September 2020|website=European Centre for Disease Prevention and Control|language=en}}&lt;/ref&gt; It may also be transmitted via [[fomite|contaminated surfaces]], although this has not been conclusively demonstrated.&lt;ref name="ECDCTRANSMIT" /&gt;&lt;ref name="WHOTRANS"&gt;{{Cite web|title=Q&amp;A: How is COVID-19 transmitted?|url=https://www.who.int/news-room/q-a-detail/q-a-how-is-covid-19-transmitted|access-date=12 July 2020|website=[[World Health Organization]] (WHO)}}&lt;/ref&gt;&lt;ref name="WHOTransBrief"&gt;{{cite web |url=https://apps.who.int/iris/rest/bitstreams/1286634/retrieve |website=[[World Health Organization|www.who.int]] |title=Transmission of SARS-CoV-2: implications for infection prevention precautions |publisher=World Health Organization |accessdate=18 September 2020 |format=PDF |date=9 July 2020 |archive-url=https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions |archive-date=9 July 2020 |url-status=live<ins class="diffchange diffchange-inline">}}&lt;/ref&gt; Airborne transmission from aerosol formation is suspected to be the main mode of transmission.&lt;ref&gt;{{cite journal |last1=Karia |first1=R. |last2=Gupta |first2=I. |last3=Khandait |first3=H. |title=COVID-19 and its Modes of Transmission |journal=SN Compr Clin Med. |date=2020 |issue=2 |pages=1798–1801 |doi=10.1007/s42399-020-00498-4 |pmid=32904860 |url=https://link.springer.com/article/10.1007%2Fs42399-020-00498-4 |accessdate=18 October 2020</ins>}}&lt;/ref&gt; It can spread from an infected person for up to two days prior to symptom onset and from people who are [[asymptomatic]].&lt;ref name="ECDCTRANSMIT" /&gt; People remain infectious for seven to twelve days in moderate cases and up to two weeks in severe cases.&lt;ref name="ECDCTRANSMIT" /&gt;&lt;ref name="ECDCQA" /&gt;&lt;!-- DO NOT REMOVE THE FOLLOWING TAG --&gt;&lt;section end="Spread" /&gt; The standard method of [[diagnosis]] is by [[Reverse transcription polymerase chain reaction|real-time reverse transcription polymerase chain reaction]] (rRT-PCR) from a [[nasopharyngeal swab]].</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984215692
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984215692&oldid=984214629


PRE
Title: Coronavirus disease 2019
ID: 984459932
FULLTEXT: <td class="diff-addedline"><div>* {{cite report | title=COVID-19 infection prevention and control measures for primary care, including general practitioner practices, dental clinics and pharmacy settings: first update | website=[[European Centre for Disease Prevention and Control]] (ECDC) | url=https://www.ecdc.europa.eu/en/publications-data/covid-19-infection-prevention-and-control-primary-care | date=October 2020 }}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984459932
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984459932&oldid=984384649


PRE
Title: Coronavirus disease 2019
ID: 984516618
FULLTEXT: <td class="diff-addedline"><div>SARS-CoV-2 is closely related to the original [[SARS-CoV]].&lt;ref name="Zhu24Jan2020"&gt;{{cite journal |vauthors=Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W |display-authors=6 |title=A Novel Coronavirus from Patients with Pneumonia in China, 2019 |journal=New England Journal of Medicine |volume=382 |issue=8 |pages=727–733 |date=February 2020 |pmid=31978945 |pmc=7092803 |doi=10.1056/NEJMoa2001017}}&lt;/ref&gt; It is thought to have an animal ([[Zoonosis|zoonotic]]) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus ''[[Betacoronavirus]]'', in subgenus [[Severe acute respiratory syndrome-related coronavirus|''Sarbecovirus'']] (lineage B) together with two bat-derived strains. It is 96% identical at the whole [[genome]] level to other bat coronavirus samples (BatCov RaTG13).&lt;ref name="WHOReport24Feb2020"&gt;{{cite report |url=https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf |title=Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) |date=24 February 2020 |publisher=[[World Health Organization]] (WHO) |access-date=21 March 2020 |archive-url=https://web.archive.org/web/20200229221222/https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf |archive-date=29 February 2020 |url-status=live}}&lt;/ref&gt;&lt;ref name="RathoreSingh"&gt;{{cite journal |last1=Rathore |first1=Jitendra Singh |last2=Ghosh |first2=Chaitali |date=25 August 2020 |title=Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview |journal=[[Pathogens and Disease]] |volume=78 |issue=6 |doi=10.1093/femspd/ftaa042|pmid=32840560 |pmc=7499575 |issn=2049-632X |oclc=823140442|doi-access=free }}&lt;/ref&gt;<ins class="diffchange diffchange-inline"> The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S).The M protein of SARS-CoV-2 is 98.6% similar to the M protein of bat SARS-CoV, maintains 98.2% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only 38% with the M protein of MERS-CoV. In silico analyses showed that the M protein of SARS-CoV-2 has a triple helix bundle, forms a single 3-transmembrane domain, and is homologous to the prokaryotic sugar transport protein SemiSWEET &lt;ref&gt;Thomas, S. The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET. Pathogens and Immunity. 2020; 5(1):342-363&lt;/ref&gt;.</ins></div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984516618
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984516618&oldid=984511310


PRE
Title: Coronavirus disease 2019
ID: 984838361
FULLTEXT: <td class="diff-addedline"><div>[[Genetics]] also plays an important role in the ability to fight off the disease. For instance, those that do not produce detectable <ins class="diffchange diffchange-inline">[[</ins>type I<ins class="diffchange diffchange-inline"> interferon]]s or produce [[Autoantibody|auto</ins>-<ins class="diffchange diffchange-inline">antibodies]] against these</ins> may get much sicker from COVID-19.&lt;ref&gt;[https://www.scientificamerican.com/article/one-in-seven-dire-covid-cases-may-result-from-a-faulty-immune-response/ One in Seven Dire COVID Cases May Result from a Faulty Immune Response]&lt;/ref&gt;&lt;ref&gt;<ins class="diffchange diffchange-inline">{{cite journal |last1=Bastard |first1=Paul |last2=Rosen |first2=Lindsey B</ins>.<ins class="diffchange diffchange-inline"> |last3=Zhang |first3=Qian |last4=Michailidis |first4=Eleftherios |last5=Hoffmann |first5=Hans-Heinrich |last6=Zhang |first6=Yu |last7=Dorgham |first7=Karim |last8=Philippot |first8=Quentin |last9=Rosain |first9=Jérémie |last10=Béziat |first10=Vivien |display-authors=et al</ins>. <ins class="diffchange diffchange-inline">|title=</ins>Auto-antibodies against type I IFNs in patients with life-threatening COVID-19<ins class="diffchange diffchange-inline"> |journal=Science |date=24 September 2020 |doi=10.1126/science.abd4585 |url=https://science.sciencemag.org/content/early/2020/09/23/science.abd4585 |accessdate=9 October 2020 |language=en |issn=0036-8075}}</ins>&lt;/ref&gt; [[Genetic screening]] is able to detect interferon effector genes.&lt;ref&gt;[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665646/ A Genetic Screen Identifies Interferon-α Effector Genes Required to Suppress Hepatitis C Virus Replication]&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984838361
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984838361&oldid=984815036


PRE
Title: Coronavirus disease 2019
ID: 984963130
FULLTEXT: <td class="diff-addedline"><div>[[Remdesivir]] is the only drug that has been approved with a specific indication to treat COVID-19.&lt;ref name="LiDeClerq"&gt;{{cite journal |vauthors=Li G, De Clercq E |title=Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |journal=Nature Reviews. Drug Discovery |volume=19 |issue=3 |pages=149–150 |date=March 2020 |pmid=32127666 |doi=10.1038/d41573-020-00016-0 |doi-access=free}}&lt;/ref&gt; In Australia and the European Union, remdesivir (Veklury) is [[Indication (medicine)|indicated]] for the treatment of COVID-19 in adults and adolescents (aged <ins class="diffchange diffchange-inline">twelve</ins> years and older with body weight at least <ins class="diffchange diffchange-inline">{{convert|</ins>40<ins class="diffchange diffchange-inline">|</ins>kg<ins class="diffchange diffchange-inline">|lb}}</ins>) with pneumonia requiring supplemental oxygen.&lt;ref&gt;{{cite web | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2020-PI-01927-1 | title=Australian Product Information – Veklury (Remdesivir) Powder For Injection | website=[[Therapeutic Goods Administration]] (TGA) | access-date=30 August 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite web | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2020-PI-01928-1 | title=Australian Product Information – Veklury (Remdesivir) Concentrate For Injection | website=[[Therapeutic Goods Administration]] (TGA) | access-date=30 August 2020}}&lt;/ref&gt;&lt;ref name="Veklury EPAR"&gt;{{cite web | title=Veklury EPAR | website=European Medicines Agency | date=23 June 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/veklury | access-date=30 August 2020}}&lt;/ref&gt; International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers.&lt;ref name="dhama"&gt;{{cite journal |vauthors=Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W |title=COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |journal=Human Vaccines &amp; Immunotherapeutics |pages=1232–1238 |date=March 2020 |volume=16 |issue=6 |pmid=32186952 |pmc=7103671 |doi=10.1080/21645515.2020.1735227 |doi-access=free}}&lt;/ref&gt;&lt;ref name="zhang2020"&gt;{{cite journal |vauthors=Zhang L, Liu Y |title=Potential interventions for novel coronavirus in China: A systematic review |journal=Journal of Medical Virology |volume=92 |issue=5 |pages=479–490 |date=May 2020 |pmid=32052466 |pmc=7166986 |doi=10.1002/jmv.25707}}&lt;/ref&gt; In March, the World Health Organization initiated the "[[Solidarity Trial]]" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy.&lt;ref name="kai"&gt;{{cite journal |last1=Kupferschmidt |first1=Kai |last2=Cohen |first2=Jon |name-list-style=vanc |title=WHO launches global megatrial of the four most promising coronavirus treatments |journal=Science Magazine |date=22 March 2020 |url=https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments |access-date=27 March 2020|doi=10.1126/science.abb8497 |doi-access=free}}&lt;/ref&gt; The World Health Organization suspended hydroxychloroquine from its global drug trials for COVID-19 treatments on 26 May 2020 due to safety concerns. It had previously enrolled 3,500 patients from 17 countries in the Solidarity Trial.&lt;ref name=20200526nytimes&gt;{{cite web |url=https://www.nytimes.com/2020/05/26/world/coronavirus-news.html |title=Citing safety concerns, the W.H.O. paused tests of a drug Trump said he had taken |date=26 May 2020 |work=[[The New York Times]]}}&lt;/ref&gt; France, Italy and Belgium also banned the use of hydroxychloroquine as a COVID-19 treatment.&lt;ref&gt;{{cite web |url=https://www.cbsnews.com/news/france-bans-use-of-hydroxychloroquine-drug-touted-by-trump-to-treat-coronavirus/ |title=France bans use of hydroxychloroquine, drug touted by Trump, in coronavirus patients |date=27 May 2020 |publisher=CBS News}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984963130
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984963130&oldid=984919487


PRE
Title: Coronavirus disease 2019
ID: 984963130
FULLTEXT: <td class="diff-addedline"><div>Remdesivir was approved for medical use in the United States in October 2020.&lt;ref name="Veklury: Summary Review"&gt;{{cite report | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000Sumr.pdf | title=Veklury: Summary Review | website=U.S. [[Food and Drug Administration]] (FDA) | access-date=22 October 2020}} {{PD-notice}}&lt;/ref&gt;&lt;ref name="FDA PR 20201022"&gt;{{cite press release | title=FDA Approves First Treatment for COVID-19 | website=U.S. [[Food and Drug Administration]] (FDA) | date=22 October 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 | access-date=22 October 2020}} {{PD-notice}}&lt;/ref&gt; It is the first treatment for COVID-19 to be approved by the U.S. [[Food and Drug Administration]] (FDA).&lt;ref name="FDA PR 20201022" /&gt; It is indicated for use in adults and adolescents (aged twelve years and older with body weight at least {{convert|40|kg|lb}}) for the treatment of COVID-19 requiring hospitalization.&lt;ref name="FDA PR 20201022" /&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984963130
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984963130&oldid=984919487


